Substance / Medication

Gamma hydroxybutyrate

Overview

Active Ingredient
oxybate
RxNorm CUI
2387302

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis.
Xu Xiao-Min, Wei You-Dong, Liu Yang et al. · Sleep Med · 2019
PMID: 31671326Meta-Analysis
Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials.
Boscolo-Berto Rafael, Viel Guido, Montagnese Sara et al. · Sleep Med Rev · 2012
PMID: 22055895Meta-Analysis
Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.
Leone Maurizio A, Vigna-Taglianti Federica, Avanzi Giancarlo et al. · Cochrane Database Syst Rev · 2010
PMID: 20166080Meta-Analysis
The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review.
Németh Zsófia, Kun Bernadette, Demetrovics Zsolt · J Psychopharmacol · 2010
PMID: 20488831Meta-Analysis
Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial.
Bavato Francesco, Schnider Laura K, Dornbierer Dario A et al. · Neuropsychopharmacology · 2025
PMID: 40229541RCTFull text (PMC)
Butanediol Conversion to Gamma-Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole.
Liakoni Evangelia, Gugelmann Hallam, Dempsey Delia A et al. · Clin Pharmacol Ther · 2019
PMID: 30450642RCTFull text (PMC)
Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring.
Dornbierer Dario A, Kometer Michael, Von Rotz Robin et al. · Eur Neuropsychopharmacol · 2019
PMID: 30824339RCT
Gamma-hydroxybutyrate increases brain resting-state functional connectivity of the salience network and dorsal nexus in humans.
Bosch Oliver G, Esposito Fabrizio, Dornbierer Dario et al. · Neuroimage · 2018
PMID: 29524621RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
4-hydroxybutyrate (substance)
SNOMED CT
259470008
UMLS CUI
C0000503
RxNorm CUI
2387302

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.